findmyKOL

Scott Tagawa, MD

Enriched profile

Professor of Medicine and Professor of Medicine in Urology; Gebroe Family Professor of Hematology-Oncology; Director, Genitourinary Oncology Program · Weill Cornell Medicine

ORCIDNPI
Region🇺🇸 New York, NY · Northeast · United StatesSpecialtyHematology / OncologyFocusProstate Cancer+9
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2024–2025

Scott Tagawa is Professor of Medicine and Professor of Medicine in Urology; Gebroe Family Professor of Hematology-Oncology; Director, Genitourinary Oncology Program at Weill Cornell Medicine. OpenAlex indexes 825 publications with 27,220 citations (h-index 71); ClinicalTrials.gov lists 16 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Scott Tagawa, MD, is Professor of Medicine and Professor of Medicine in Urology at Weill Cornell Medicine (NewYork-Presbyterian – Weill Cornell Medical Center). The public record shows 825 publications with 27,220 citations (h-index 71), centered on Prostate Cancer, Kidney Cancer / RCC, Breast Cancer. It also documents an investigator role on 16 registered clinical trials, industry payments reported by 36 companies, 1 NIH-funded awards (2024–2025).

  • Most recent indexed publication: 2026 · Science advances
  • Top research focus: Prostate Cancer
  • 16 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 36 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Prostate Cancer14 trialsKidney Cancer / RCC2 trialsBreast Cancer1 trialLung Cancer (NSCLC/SCLC)1 trialColorectal Cancer1 trialPancreatic Cancer1 trialGastroesophageal Cancer1 trialOvarian / Gynecologic Cancer1 trialHead & Neck Cancer1 trialNeuro-Oncology / Glioma1 trialRectal Neoplasms1 trialEsophageal Neoplasms1 trialGlioma1 trialSmall Cell Lung Carcinoma1 trialKidney Neoplasms1 trialProstatic Neoplasms, Castration-Resistant1 trial

Research focus

OpenAlex concept fingerprint
Prostate CancerKidney Cancer / RCCBreast CancerColorectal CancerGastroesophageal CancerHead & Neck CancerLung Cancer (NSCLC/SCLC)Neuro-Oncology / GliomaOvarian / Gynecologic CancerPancreatic Cancer

Drugs & molecules

across trials, industry payments and publications
Xtandigeneric · EnzalutamideClinical trialsIndustry payments31Publications5Trodelvygeneric · SacituzumabClinical trialsIndustry payments14Publications5Keytrudageneric · PembrolizumabClinical trialsIndustry payments9Publications3

Works with

trial sponsors and companies reporting payments
Telix PharmaceuticalsClinical trialsIndustry payments47Pfizer Inc.Clinical trialsIndustry payments42Merck Sharp & Dohme LLCClinical trialsIndustry payments35

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
825publications

Distinct works indexed by OpenAlex, matched via ORCID; 58 in PubMed.

27,220citations

Total citations across indexed works.

71h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
16clinical trials

Investigator role on registered studies.

View trials
36companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
1NIH grants · 2024–2025

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 16 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

36 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    55.6%
    Corticosteroid55.6%
    Prednisone100%
    Part D<11 patients
  • Nervous system

    44.4%
    Gabapentinoids44.4%
    Gabapentin100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

1 NIH research award on record, funded 20242025 per NIH RePORTER. The latest:

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/scott-tagawa-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • ResearchGate

    researchgate.net/profile/Scott-Tagawa

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net
  • X / Twitter

    x.com/drscotttagawa

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com
1 more verified account behind the reveal.Reveal →

Mentions by others

where others cite or feature them
  • Facebook

    facebook.com/OncLive/videos/scott-t-tagawa-md-ms-facp-fasco-of-weill-cornell-medicine-details-factors-to-con/1521201145733828

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →facebook.com
  • Other

    nyp.org/advances/podcast/phase-3-trial-reduces-risk-of-progression-in-metastatic-prostate-cancer

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyp.org
  • Other

    prostatehealthpodcast.com/56-prostate-specific-membrane-antigen-psma-targeting-in-prostate-cancer-treatment-scott-tagawa-m-d

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →prostatehealthpodcast.com
1 more mention behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • M.S. in Clinical Investigation

    Weill Cornell Graduate School of Medical Sciences

    2010
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org
  • M.D.

    University of Southern California School of Medicine

    1998
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org
  • B.S.

    Georgetown University

    1993
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org
  • Board Certified

    American Board of Internal Medicine (Internal Medicine, Hematology, and Medical Oncology)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org
  • verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org

Editorial & leadership roles

journal and society appointments

Awards & honors

honors on the public record
1 more award behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances
  • GU Oncology Now podcast

    "Scott Tagawa, MD, on PSMA PET-CT" (Parts 1 & 2)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →guoncologynow.com
  • The Prostate Health Podcast

    Ep. 56, "PSMA-Targeting in Prostate Cancer Treatment"

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →prostatehealthpodcast.com
  • NewYork-Presbyterian "Advances in Care" podcast

    Ep. 42, PSMAddition Phase 3 trial results

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyp.org
1 more media item behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.